| 1.86 -0.18 (-8.82%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.62 | 1-year : | 3.06 |
| Resists | First : | 2.25 | Second : | 2.62 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.5 | Second : | 1.04 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 1.55 |
| MA(100) : | 0.99 |
MA(250) : | 0.86 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 80.7 |
D(3) : | 81.3 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 2.74 | Low : | 0.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IVVD ] has closed below upper band by 32.6%. Bollinger Bands are 133% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.21 | 2.21 - 2.23 |
| Low: | 1.83 - 1.84 | 1.84 - 1.85 |
| Close: | 1.84 - 1.86 | 1.86 - 1.88 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Fri, 17 Oct 2025
Invivyd (IVVD): Valuation Spotlight as FDA Clears Next-Generation COVID-19 Antibody Trials - simplywall.st
Tue, 14 Oct 2025
Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31% - Sahm
Tue, 07 Oct 2025
Are Investors Undervaluing Invivyd, Inc. (NASDAQ:IVVD) By 31%? - 富途牛牛
Mon, 06 Oct 2025
Invivyd stock soars after FDA clears IND for COVID antibody candidate - Investing.com
Mon, 06 Oct 2025
Invivyd Receives U.S. IND Clearance for VYD2311; Trials Start 2025 | IVVD Stock News - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 214 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 19.2 (%) |
| Held by Institutions | 60.7 (%) |
| Shares Short | 6,490 (K) |
| Shares Short P.Month | 5,270 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | -238.4 % |
| Operating Margin | -127.8 % |
| Return on Assets (ttm) | -53.3 % |
| Return on Equity (ttm) | -120.1 % |
| Qtrly Rev. Growth | 420.6 % |
| Gross Profit (p.s.) | 0.2 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -113 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -2.03 |
| PEG Ratio | 0 |
| Price to Book value | 5.16 |
| Price to Sales | 8.63 |
| Price to Cash Flow | -3.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|